Returns as of 12/09/2021
Returns as of 12/09/2021
Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.
Motley Fool Issues Rare “All In” Buy Alert
You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Shares of Novavax ( NVAX -0.60% ) were soaring 24.1% higher as of 12:35 p.m. ET on Tuesday. The big gain came after two positive developments for the company.
European Medicines Agency head Emma Cooke told European Union health ministers on Tuesday that Novavax’s COVID-19 vaccine could be authorized in the “near future.” Also, a study led by the University of Oxford found that a second dose of Novavax’s vaccine following an initial dose of AstraZeneca‘s ( AZN 0.68% ) vaccine was significantly more effective than two doses of the AstraZeneca vaccine.
Image source: Getty Images.
It’s certainly not surprising that the vaccine stock jumped so much with these stories emerging today. The more important of the two is the possibility that Novavax’s vaccine could soon win EU authorization.
Novavax has a supply agreement in place with the EU to provide up to 200 million doses of its COVID-19 vaccine pending authorization. The company could soon begin to generate significant revenue if that authorization is right around the corner.
However, the University of Oxford study is also encouraging for Novavax. It could increase the likelihood that Novavax’s vaccine is used as a second dose in countries that are early in their vaccination efforts and that have authorized the AstraZeneca vaccine.
The potential EU authorization isn’t the only one that Novavax awaits. The company has also filed for regulatory approvals or authorizations in Australia, Canada, India, New Zealand, Singapore, and the United Kingdom. Novavax plans to submit for U.S. Emergency Use Authorization of its COVID-19 vaccine by year-end.
Why do we invest this way? Learn More
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Market-beating stocks from our award-winning service.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/09/2021.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns as of January 1, 2021.
Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool’s premium services.
Making the world smarter, happier, and richer.
Market data powered by Xignite.